MeiraGTx Holdings plc (MGTX)
Nasdaq · Healthcare · Biotechnology
$10.92+1.20%as of Oct 6, 2026, 1:35 AM ET
- Market cap
- $1.0B
- P/E (trailing)
- 12.6
- 52-week range
- $6.62 – $15.35
- 52-week change
- +27.09%
- EPS (trailing)
- $0.87
- Analyst rating
- 1.5 Strong buy
- Next earnings
- Nov 12, 2026
Fiscal year to Dec 2025
- Revenue
- $81.4M (+144.57%)
- Operating margin
- −130.2%
- Diluted EPS
- −$1.42
- Free cash flow
- −$50.2M
From the company’s annual report on SEC EDGAR.
About MeiraGTx Holdings plc
MeiraGTx Holdings plc, a clinical-stage genetic medicines company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases; neurodegenerative diseases; and xerostomia. It is also develops AAV-AQP1 for radiation-induced grade 2/3 radiation-induced xerostomia, as well as for Sjogren's syndrome; AAV-GAD in Phase 2 trial for Parkinson's disease; AAV-RPE65 in Phase 2 trial for RPE65-associated retinal dystrophy; and AAV-CNGB3 and AAV-CNGA3, which are both in Phase ½ clinical trial for achromatopsia, as well as offers AAV-AIPL1 for Leber congenital amaurosis (LCA) 4. In addition, the company's products under preclinical development include AAV-RDH12 for retinol dehydrogenase 12 mutation-associated retinal dystrophy; AAV-BBS10 for Bardet-Biedl syndrome (BBS) due to BBS10 mutations; AAV-RetGC for LCA type 1; and AAV-UPF1 for amyotrophic lateral sclerosis, as well as programs for Alzheimer's disease, and wet and dry neovascular age related macular degeneration.
Headquarters: New York, United States · 393 employees · meiragtx.com